# A Study of E6011 in Participants With Active Crohn's Disease

> **NCT03733314** · PHASE2 · COMPLETED · sponsor: **EA Pharma Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** E6011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03733314
- **Lead sponsor:** EA Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-25
- **Primary completion:** 2022-03-16
- **Final completion:** 2024-04-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733314, "A Study of E6011 in Participants With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03733314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*